At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 61 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS
In Brief
A Phase 1 clinical trial evaluating Liraglutide and Placebo for Obesity. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2017
Primary CompletionJan 2018
TodayJul 2026
First PostedFeb 3, 2017
Enrollment StartFeb 20, 2017
Primary CompletionJan 16, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago
Interventions
Liraglutidedrug
Liraglutide
Placeboother
Placebo